Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Synonyms
Levetiracetam
Lévétiracetam
Levetiracetame
Levetiracetamum
Brand Names
Levetiracetam Accord
Elepsia XR 1500 mg
Levetiracetam Actavis Group
LEVETIRACETAM Extended-release
Priva-levetiracetam
Levetiracetam 1000 mg
Tva-levetiracetam
Levetiracetam Sun
Levetiracetam Teva
Teva-levetiracetam
Levetiracetam in Sodium Chloride
Jamp-levetiracetam
Abbott-levetiracetam
Bio-levetiracetam
Levetiracetam 750 mg
Van-levetiracetam
Levetiractam
Ach-levetiracetam
Spritam
Levetiracetam Injection USP
Roweepra XR
Ag-levetiracetam
Auro-levetiracetam
Torrent-levetiracetam
Dom-levetiracetam
M-levetiracetam
Matever
Levetiracetam 250 mg
Nra-levetiracetam
Levetiracetam Actavis
Pharma-levetiracetam
Riva-levetiracetam
Ran-levetiracetam
Jamp Levetiracetam Tablets
Levertiracetam
Pro-levetiracetam - 250
Mint-levetiracetam
Nat-levetiracetam
Levetiracetam Hospira
Keppra XR
Keppra
Apo-levetiracetam
Elepsia XR 1000 mg
Levetiracetam Extended-release
PHL-levetiracetam
Roweepra
Levetiracetam Extended-Release
Elepsia XR
Pdp-levetiracetam
Sandoz Levetiracetam
Levetiracetam Levetiracetam
Nu-levetiracetam
Levetiracetam extended-release
Levetiracetam ER
Levetiracetam Micro
PMS-levetiracetam
Levetiracetam Extended Release
Pro-levetiracetam - 750
Ava-levetiracetam
Mint-levetiracetam Solution
Novo-levetiracetam
Levetiracetam Ratiopharm
Levetiracetam
LEVETIRACETAM solution
Pro-levetiracetam - 500
Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Categories
Acetamides
Amides
Anticonvulsants
Central Nervous System Agents
Central Nervous System Depressants
Decreased Central Nervous System Disorganized Electrical Activity
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682